Download PDF
Synlett 2006(13): 2067-2070  
DOI: 10.1055/s-2006-949610
LETTER
© Georg Thieme Verlag Stuttgart · New York

New Cyclic Arg-Gly-Asp Pseudopentapeptide Containing the β-Turn Mimetic GPTM

Maria Salvatia, Franca M. Cordero*a, Federica Pisaneschia, Nicoletta Cinib, Anna Bottoncettib, Alberto Brandi*a
a Department of Organic Chemistry ‘Ugo Schiff’, Laboratory of Design, Synthesis and Study of Biologically Active Heterocycles, University of Firenze, via della Lastruccia 13, 50019 Sesto Fiorentino (FI), Italy
Fax: +39(055)4573531; e-Mail: franca.cordero@unifi.it; e-Mail: alberto.brandi@unifi.it;
b Department of Clinical Physiopathology, Nuclear Medicine Unit, University of Firenze, viale G. Pieraccini 6, 50134 Firenze, Italy
Further Information

Publication History

Received 31 May 2006
Publication Date:
09 August 2006 (online)

    Permissions and Reprints All articles of this category

Abstract

The solid-phase synthesis of cyclic pseudopeptides containing the Arg-Gly-Asp recognition sequence and the dipeptide isostere 2-amino-3-oxotetrahydro-1H-pyrrolizine-7a(5H)-carboxylic acid (GPTM) was accomplished. N-Fmoc-Asp-OAll was anchored to Wang resin through its side chain and sequentially coupled with N-Fmoc-Gly-OH, N-Fmoc-Arg(Pbf)-OH and N-Fmoc-GPTM-OH. The supported linear pentapeptide smoothly underwent head-to-tail cyclization by activation with TBTU/DIPEA. Finally, TFA treatment released the completely deprotected cyclic pseudopentapeptide. Competition binding assays to purified α V β3 and α V β5 integrins showed a high inhibitory activity of cyclo[Arg-Gly-Asp-(2S,7aS)-GPTM].

Key words

cyclic peptides - solid-phase synthesis - heterocycles - integrin antagonists - dipeptide isosteres

    References and Notes

  • For recent reviews, see:
  • 1a Arnaout MA. Goodman SL. Xiong JP. Curr. Opin. Cell Biol.  2002,  14:  641 
    Google Scholar
  • 1b Hynes RO. Cell  2002,  110:  673 
    Google Scholar
  • 1c Plow EF. Haas TA. Zhang L. Loftus J. Smith JW. J. Biol. Chem.  2000,  275:  21785 
    Google Scholar
  • 1d Humphries MJ. Biochem. Soc. Trans.  2000,  28:  311 
    Google Scholar
  • 2a Eliceiri BP. Cheresh DA. Cancer J.  2000,  13:  245 
    CrossrefGoogle Scholar
  • 2b Burke PA. De Nardo SJ. Miers LA. Lamborn KL. Matzku S. De Nardo GL. Cancer Res.  2002,  62:  4263 
    CrossrefGoogle Scholar
  • 2c Haubner R. Finsinger D. Kessler H. Angew. Chem., Int. Ed. Engl.  1997,  36:  1374 
    CrossrefGoogle Scholar
  • 3a Marinelli L. Gottschalk KE. Meyer A. Novellino E. Kessler H. J. Med. Chem.  2004,  47:  4166 
    Google Scholar
  • 3b Friedlander M. Theesfeld CL. Sugita M. Fruttiger M. Thomas MA. Chang S. Cheresh DA. Proc. Natl. Acad. Sci. U.S.A.  1996,  93:  9764 
    Google Scholar
  • 3c Friedlander M. Brooks PC. Shaffer RW. Kincaid CM. Varner JA. Cheresh DA. Science  1995,  270:  1550 
    Google Scholar
  • 4 Ruoslathi E. Pierschbacher MD. Science  1987,  238:  491 
    CrossrefGoogle Scholar
  • 5 Haubner R. Gratias R. Diefenbach B. Goodman SL. Jonczyk A. Kessler H. J. Am. Chem. Soc.  1996,  118:  7461 
    CrossrefGoogle Scholar
  • 6a Bach AC. Espina JR. Jackson SA. Stouten PFW. Duke JL. Mousa SA. DeGrado WF. J. Am. Chem. Soc.  1996,  118:  293 
    CrossrefGoogle Scholar
  • 6b Dechantsreiter M. Plnaker E. Mathä B. Lohof E. Hölzemann G. Jonczyk A. Goodman SL. Kessler H. J. Med. Chem.  1999,  42:  3033 
    CrossrefGoogle Scholar
  • 6c Lohof E. Plnaker E. Mang C. Burkhart F. Dechantsreiter MA. Haubner R. Wester HJ. Schwaiger M. Hölzemann G. Goodman SL. Kessler H. Angew. Chem. Int. Ed.  2000,  39:  2761 
    CrossrefGoogle Scholar
  • 6d Belvisi L. Bernardi A. Checchia A. Manzoni L. Potenza D. Scolastico C. Castorina M. Capelli A. Giannini G. Carminati P. Pisano C. Org. Lett.  2001,  3:  1001 
    CrossrefGoogle Scholar
  • 6e Belvisi L. Bernardi A. Colombo M. Manzoni L. Potenza D. Scolastico C. Giannini G. Marcellini M. Riccioni T. Castorina M. LoGiudice P. Carminati P. Pisano C. Bioorg. Med. Chem.  2006,  14:  169 
    CrossrefGoogle Scholar
  • 7a Pitts WJ. Wityak J. Smallheer JM. Tobin AE. Jetter JW. Buynitsky JS. Harlow PP. Solomon KA. Corjay MH. Mousa SA. Wexler RR. Jadhav PK. J. Med. Chem.  2000,  43:  27 
    CrossrefGoogle Scholar
  • 7b Batt DG. Petraitis J. Houghton GC. Modi DP. Cain GA. Corjay MH. Mousa SA. Bouchard PJ. Forsythe MS. Harlow PP. Barbera FA. Spitz SM. Wexler RR. Jadhav PK. J. Med. Chem.  2000,  43:  41 
    CrossrefGoogle Scholar
  • 8a Pisaneschi F. Gensini M. Salvati M. Cordero FM. Brandi A. Heterocycles  2006,  67:  413 
    CrossrefGoogle Scholar
  • 8b Salvati M. Cordero FM. Pisaneschi F. Bucelli F. Brandi A. Tetrahedron  2005,  61:  8836 
    CrossrefGoogle Scholar
  • 8c Cordero FM. Pisaneschi F. Salvati M. Valenza S. Faggi C. Brandi A. Chirality  2005,  17:  149 
    CrossrefGoogle Scholar
  • 8d Cordero FM. Pisaneschi F. Meschini Batista K. Valenza S. Machetti F. Brandi A. J. Org. Chem.  2005,  70:  856 
    CrossrefGoogle Scholar
  • 8e Cordero FM. Valenza S. Machetti F. Brandi A. Chem. Commun.  2001,  1590 
    CrossrefGoogle Scholar
  • 9 For a recent review on azabicyclic dipeptide mimetics, see: Maison W. Prenzel AHGP. Synthesis  2005,  1031 
    Article in Thieme ConnectGoogle Scholar
  • For recent reviews, see:
  • 10a Davies JS. J. Pept. Sci.  2003,  9:  471 
    Google Scholar
  • 10b Lambert JN. Mitchell P. Roberts KD. J. Chem. Soc., Perkin Trans. 1  2001,  5:  471 
    Google Scholar
  • 10c Romanovskis P. Spatola AF. J. Pept. Res.  1998,  52:  356 
    Google Scholar
  • 11a Mazur S. Jayalekshmy P. J. Am. Chem. Soc.  1979,  101:  677 
    Google Scholar
  • 11b Albericio F. Hammer RP. García-Echeverría C. Molins MA. Cheng JL. Munson MC. Pons M. Giralt E. Barany G. Int. J. Pept. Protein Res.  1991,  37:  402 
    Google Scholar
  • 12a Alcaro MC. Sabatino G. Uziel J. Chelli M. Ginanneschi M. Rovero P. Papini AM. J. Pept. Sci.  2004,  10:  218 
    CrossrefGoogle Scholar
  • 12b Chaleix V. Sol V. Guilloton M. Granet R. Krausz P. Tetrahedron Lett.  2004,  45:  5295 
    CrossrefGoogle Scholar
  • 12c Royo M. Farrera-Sinfreu J. Solé L. Albericio F. Tetrahedron Lett.  2002,  43:  2029 
    CrossrefGoogle Scholar
  • 12d McCusker CF. Kocienski PJ. Botle FT. Schätzlein AG. Bioorg. Med. Chem.  2002,  12:  547 
    CrossrefGoogle Scholar
  • 12e Akaji K. Teruya K. Akaji M. Aimoto S. Tetrahedron  2001,  57:  2293 
    CrossrefGoogle Scholar
  • 12f Delforge D. Art M. Gillon B. Die M. Delaive E. Raes M. Remacle J. Anal. Biochem.  1996,  242:  180 
    CrossrefGoogle Scholar
  • 12g Kates SA. Daniels SB. Albericio F. Anal. Biochem.  1993,  212:  303 
    CrossrefGoogle Scholar
  • 13 Kaiser E. Colescott RL. Bossinger CD. Cook PI. Anal. Biochem.  1970,  34:  595 
    CrossrefPubMedGoogle Scholar
  • 14 Krchnak V. Vagner J. Safar P. Lebl M. Collect. Czech. Chem. Commun.  1988,  53:  2542 
    Google Scholar
  • 16 Kumar CC. Nie H. Rogers CP. Malkowski M. Maxwell E. Catino JJ. Armstrong L. J. Pharm. Exp. Ther.  1997,  283:  843 
    Google Scholar
15

Analytical Data for Cyclo[Arg-Gly-Asp-(2S,7aS)-GPTM] (3). Yield of 14% with respect to N-Fmoc-Asp(Wang-resin)-OAll loading; [α]D 20 +44.0 (c 0.3, H2O). 1H NMR (400 MHz, D2O): δ = 4.10 (t, J = 7.7 Hz, 1 H, H-Cα Arg), 4.05 (d, J = 14.2 Hz, 1 H, H-Cα Gly), 3.42 (d, J = 14.1 Hz, 1 H, H-Cα Gly), 3.34 (dt, J = 11.7, 8.2 Hz, 1 H, 5-Ha GPTM), 3.16-3.02 (m, 3 H, 5-Hb GPTM, H-Cδ Arg), 2.78 (dd, J = 7.6, 6.0 Hz, 2 H, H-Cβ Asp), 2.47 (dd, J = 14.3, 8.2 Hz, 1 H, 1-Ha GPTM), 2.29 (dd, J = 12.3, 5.7 Hz, 1 H, 7-Ha GPTM), 2.13 (d, J = 14.3 Hz, 1 H, 1-Hb GPTM), 2.12-2.08 (m, 1 H, 6-Ha GPTM), 1.84-1.77 (m, 1 H, 7-Hb GPTM), 1.70 (q, J = 7.7 Hz, 2 H, H-Cβ Arg), 1.62-1.43 (m, 3 H, 6-Hb GPTM, H-Cγ Arg). 1H NMR (400 MHz, DMSO-d 6): δ = 12.20 (br s, 1 H, CO2H), 8.66 (br t, J = 6.1 Hz, 1 H, NH Gly), 8.41 (d, J = 6.8 Hz, 1 H, NH Arg), 8.28 (d, J = 9.0 Hz, 1 H, NH GPTM), 7.44 (br s, 2 H, NH2 Arg), 7.40-7.38 (m, 1 H, C=NH Arg), 7.13 (d, J = 9.2 Hz, 1 H, NH Asp), 4.56 (dt, J = 8.4, 5.1 Hz, 1 H, 2-H GPTM), 4.47 (dt, J = 8.5, 4.3 Hz, 1 H, H-Cα Asp), 4.07 (q, J = 7.2 Hz, 1 H, H-Cα Arg), 4.00 (dd, J = 13.9, 7.8 Hz, 1 H, H-Cα Gly), 3.48-3.45 (m, 1 H, 5-Ha GPTM), 3.19 (dd, J = 13.9, 4.4 Hz, 1 H, H-Cα Gly), 3.12-3.07 (m, 2 H, H-Cδ Arg), 2.99-2.92 (m, 1 H, 5-Hb GPTM), 2.69 (dd, J = 16.7, 8.4 Hz, 1 H, 1-Ha GPTM), 2.41 (dd, J = 16.7, 4.8 Hz, 1 H, 1-Hb GPTM), 2.34-2.29 (m, 3 H, 7-Ha GPTM, H-Cβ Asp), 2.09 (d, J = 14.0 Hz, 1 H, 7-Hb GPTM), 1.85-1.77 (m, 1 H, 6-Ha GPTM), 1.73-1.42 (m, 5 H, 6-Hb GPTM, H-Cβ Arg, H-Cγ Arg). 13C NMR (100 MHz, D2O): δ = 179.8, 177.41, 177.36, 174.4, 173.7, 173.5 (s, CO), 159.3 (s, CN), 77.3 (s, C-7a GPTM), 58.9 (d, C-2 GPTM), 57.7 (d, Cα Arg), 51.6 (d, Cα Asp), 46.5 (t, Cα Gly), 43.5 (t, C-5 GPTM), 43.0 (t, Cδ Arg), 41.7 (t, C-1 GPTM), 37.1 (t, Cβ Asp), 36.8 (t, C-7 GPTM), 28.7 (t, Cβ Arg), 28.5 (t, Cγ Arg), 27.0 (t, C-6 GPTM). MS (ESI): 495 [MH+].

17

The reproducibility of the IC50 values was proved by performing the same tests on the antagonist cyclo(-Temp8-Arg-Gly-Asp-) reported by Belvisi et al. in ref. 6e.